Cancer Clinical Investigation

Search results

• HEALTH CARE SECTOR DAILY: ANNOUNCEMENTS AND PRESS RELEASES OF LISTED COMPANIES WEDNESDAY APRIL 06, 2022

  Charles Powell

  6/04/22

  1 item of Media coverage

  Press/Media

• Sema4 And Mount Sinai Use Integrative Network Analysis To Identify Potential New Lung Cancer Therapy

  Charles Powell

  5/04/22

  13 items of Media coverage

  Press/Media

• Immunotherapy Before Liver Cancer Surgery Can Kill Tumor, and Likely Residual Cancer Cells

  Thomas Marron & Miriam Merad

  19/01/22 → 3/04/22

  11 items of Media coverage

  Press/Media

• US Patent Issued to Icahn School of Medicine at Mount Sinai on March 29 for "Compositions and methods for treating CDK4/6-mediated cancer" (New York, New Jersey Inventors)

  XUEWEI WU & Poulikos Poulikakos

  30/03/22

  1 item of Media coverage

  Press/Media

• New Method to Identify Early-stage Lung Cancers Identified

  Charles Powell

  26/03/22

  1 item of Media coverage

  Press/Media

• Mount Sinai Researchers Develop Novel Method to Identify and Treat Aggressive Early-Stage Lung Cancers

  Charles Powell

  24/03/22 → 26/03/22

  5 items of Media coverage

  Press/Media

• Identify and Treat Aggressive Early-Stage Lung Cancers

  Charles Powell

  25/03/22

  1 item of Media coverage

  Press/Media

• Researchers develop novel method to identify and treat aggressive early-stage lung cancers

  Charles Powell

  24/03/22 → 25/03/22

  2 items of Media coverage

  Press/Media

• Novel method to identify and treat aggressive early-stage lung cancers

  Charles Powell

  24/03/22

  1 item of Media coverage

  Press/Media

• FDA approves Janssen's Carvykti for multiple myeloma.(RX Retail Pharmacy: BRANDED DRUGS)

  Sundar Jagannath

  14/03/22

  1 item of Media coverage

  Press/Media

• FDA Approves Carvykti (ciltacabtagene autoleucel) BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  9/03/22

  1 item of Media coverage

  Press/Media

• United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  7/03/22

  2 items of Media coverage

  Press/Media

• Carvykti Approved for Relapsed/Refractory Multiple Myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media

• U.S FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media

• US FDA approves Janssen Pharma's Carvykti to treat relapsed or refractory multiple myeloma

  Sundar Jagannath

  2/03/22

  1 item of Media coverage

  Press/Media

• Janssen first cell therapy CARVYKTI gets USFDA nod

  Sundar Jagannath

  1/03/22

  3 items of Media coverage

  Press/Media

• Janssen's Cilta-Cel CAR T Receives FDA Approval for Relapsed Multiple Myeloma

  Sundar Jagannath

  1/03/22

  1 item of Media coverage

  Press/Media

• FDA Approves Carvykti for Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  1/03/22

  2 items of Media coverage

  Press/Media

• Janssen's First Cell Therapy Approved by FDA for Patients with Multiple Myeloma

  Sundar Jagannath

  1/03/22

  2 items of Media coverage

  Press/Media

• U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  1/03/22

  6 items of Media coverage

  Press/Media

• U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

  Sundar Jagannath

  28/02/22 → 1/03/22

  37 items of Media coverage

  Press/Media

• FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma

  Sundar Jagannath

  1/03/22

  1 item of Media coverage

  Press/Media

• U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma'

  Sundar Jagannath

  28/02/22

  1 item of Media coverage

  Press/Media

• Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End Points

  Thomas Marron

  26/02/22

  1 item of Media coverage

  Press/Media

• Pre-Op Treatment May Be Advance Against Deadly Liver Cancers

  Thomas Marron

  28/01/22 → 3/02/22

  170 items of Media coverage

  Press/Media